Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab in adolescents with chronic migraine
NCT04616326Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2020
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Galcanezumab with Placebo (2 arms). Primary endpoint: Monthly Migraine Headache Days at 3 months. Started Nov 2020; status: active, not recruiting.
02
Drugs
galcanezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT04616326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616326.